Embolic Protection Devices Market Worth $604.9 Million – In Depth Analysis of Industry Segments and Key Players

Embolic Protection Devices Market

Posted on 2021-09-09 by MarketsandMarkets in Pharmaceuticals // 0 Comments

PUNE, India, 2021-Sep-09 — /EPR Network/ —

According to the new market research report “Embolic Protection Devices Market by Type (Distal Filter, Distal Occlusion, Proximal Occlusion), Material (Nitinol, Polyurethane), Application (Cardiovascular, Neurovascular, Peripheral), Indication (PCI, SVD, TAVR) – Global Forecast”, published by MarketsandMarkets™, is projected to reach USD 604.9 Million by 2023 from USD 405.5 Million in 2018, at a CAGR of 8.3% during the forecast period.

Browse and in-depth TOC on “Embolic Protection Devices Market”
127 – Tables
28 – Figures
172 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158143803

The growth in market is mainly attributed to factors such as the rising incidence of cardiovascular and neurovascular diseases, growing funding and investments, launch of technologically advanced embolic protection devices, and the rising demand for minimally invasive procedures.

The neurovascular segment is expected to grow at the highest CAGR during the forecast period

On the basis of application, the Embolic Protection Devices Market is categorized into cardiovascular, neurovascular, and peripheral vascular diseases. The neurovascular segment is expected to grow at the highest CAGR during the forecast period. The favorable medical reimbursement scenarios for neurovascular procedures in developed countries, increasing awareness about the clinical efficacy of embolic protection devices among neurosurgeons, and the rising adoption of these systems across developing countries (such as China and India) are expected to drive the growth of this application segment during the forecast period.

The percutaneous coronary intervention segment accounted for the largest market share in 2017

On the basis of indication, the market is categorized into percutaneous coronary intervention, transcatheter aortic valve replacement (TAVR), carotid artery diseases, saphenous vein graft disease, and other indications. In 2017, the percutaneous coronary intervention segment accounted for the largest share of the global embolic protection devices market. The large share of this segment can primarily be attributed to the increasing prevalence of CAD and the rising preference for minimally invasive procedures.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=158143803

Hospitals are expected to be the largest end users of embolic protection devices during the forecast period

The major end users of embolic protection devices market are hospitals and ambulatory surgical centers. The hospital segment is expected to grow at the highest CAGR during the forecast period. The market for this segment is mainly driven by factors such as the growing number of angioplasty procedures performed in hospitals, rising incidence of chronic vascular diseases, favorable reimbursement scenario in developed countries, growing number of hospitals, and increasing government initiatives to provide quality treatment for cardiovascular diseases.

North America dominated the market in 2017, and APAC is expected to grow at the highest CAGR

In 2017, North America dominated the embolic protection devices market. The rising geriatric population and prevalence of cardiovascular and neurovascular diseases, increasing adoption of minimally invasive techniques, increasing availability of funding, and the presence of a large number of medical device product manufacturers are driving the growth of the market in North America. However, the APAC is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to the growing geriatric population, rising prevalence of CVD, increasing number of facilities, and rising healthcare expenditure.

The prominent players in the embolic protection devices market are Boston Scientific (US), Medtronic (Ireland), Abbott (US), Cordis (A Cardinal Health Company) (US), Allium Medical (Israel), Contego Medical (US), W.L. Gore & Associates (US), Silk Road Medical (US), Claret Medical (US), and AngioSlide (Israel).

Matched content

Editor’s pick